Status:
COMPLETED
HSP-glomerulonephritis Trial: MP vs CyA
Lead Sponsor:
Oulu University Hospital
Conditions:
Purpura, Schoenlein-Henoch
Eligibility:
All Genders
2-18 years
Phase:
PHASE4
Brief Summary
No curative treatment of severe HSP nephritis is known. Apart from corticosteroids, immunosuppressive drugs, such as azathioprine and cyclophosphamide, have been used to treat severe HSP nephritis.Li...
Detailed Description
Using a prospective, randomised, open-labelled design, MP pulse treatment and cyclosporine A treatment will be compared for their efficacy in the treatment of severe HSP glomerulonephritis. The trial...
Eligibility Criteria
Inclusion
- On the basis of a renal biopsy, the patient has been diagnosed for crescentic HSP glomerulonephritis of ISKDC grade III or IV or HSP glomerulonephritis of ISKDC grade II + a definite nephrotic syndrome (proteinuria \> 40 mg/m2/h).
Exclusion
- The child is on regular medication known to interact with cyclosporine. Such medication includes cisapride, phenytoin, phenobarbital, carbamazepine, digoxin and anti-inflammatory pain medication.
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00425724
Start Date
January 1 2000
End Date
February 1 2011
Last Update
August 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Pediatrics, Oulu University Hospital
Oulu, Finland, 90029 OYS